ClinicalTrials.gg

Program

EDP-323

A development code. Also written as “EDP-323 Dose Regimen 1” and “EDP-323 Dose Regimen 2”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by Enanta Pharmaceuticals.

Furthest: phase 2, since Nov 27, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Enanta Pharmaceuticals40 open or runningphase 2since Nov 27, 2023Oct 17, 2022none ahead

Also a collaborator on its studies: hvivo-services-limited.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2022First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT05587478 · 82 enrolled · United States
  2. Nov 27, 2023Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06170242 · 142 enrolled · United Kingdom
  3. Feb 21, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06847464 · 48 enrolled · United States
  4. Apr 1, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT06917508 · 24 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06917508Respiratory Syncytial Virus Infections · United States1CompletedJun 6, 202524
NCT06847464Respiratory Syncytial Virus Infections · United States1CompletedMay 24, 202548
NCT06170242Respiratory Syncytial Virus Infections · United Kingdom2CompletedJun 17, 2024142
NCT05587478Respiratory Syncytial Virus Infections · United States1CompletedMar 29, 202382

How it is read

Names in the registry

  • “EDP-323”, 6 entries
  • “EDP-323 Dose Regimen 1”, 1 entry
  • “EDP-323 Dose Regimen 2”, 1 entry

Codes read as this program: EDP323.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.